GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » EV-to-FCF

Ludwig Enterprises (Ludwig Enterprises) EV-to-FCF : -203.06 (As of Jun. 04, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ludwig Enterprises's Enterprise Value is $34.72 Mil. Ludwig Enterprises's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.17 Mil. Therefore, Ludwig Enterprises's EV-to-FCF for today is -203.06.

The historical rank and industry rank for Ludwig Enterprises's EV-to-FCF or its related term are showing as below:

LUDG' s EV-to-FCF Range Over the Past 10 Years
Min: -212.36   Med: 0   Max: 0
Current: -203.06

LUDG's EV-to-FCF is ranked worse than
100% of 360 companies
in the Medical Devices & Instruments industry
Industry Median: 27.715 vs LUDG: -203.06

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Ludwig Enterprises's stock price is $0.21. Ludwig Enterprises's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.011. Therefore, Ludwig Enterprises's PE Ratio for today is At Loss.


Ludwig Enterprises EV-to-FCF Historical Data

The historical data trend for Ludwig Enterprises's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises EV-to-FCF Chart

Ludwig Enterprises Annual Data
Trend Dec22 Dec23
EV-to-FCF
-196.64 -34.47

Ludwig Enterprises Quarterly Data
Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial - - - -34.47 -235.07

Competitive Comparison of Ludwig Enterprises's EV-to-FCF

For the Medical Devices subindustry, Ludwig Enterprises's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ludwig Enterprises's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ludwig Enterprises's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Ludwig Enterprises's EV-to-FCF falls into.



Ludwig Enterprises EV-to-FCF Calculation

Ludwig Enterprises's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=34.724/-0.171
=-203.06

Ludwig Enterprises's current Enterprise Value is $34.72 Mil.
Ludwig Enterprises's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ludwig Enterprises  (OTCPK:LUDG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ludwig Enterprises's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.21/-0.011
=At Loss

Ludwig Enterprises's share price for today is $0.21.
Ludwig Enterprises's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.011.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Ludwig Enterprises EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ludwig Enterprises (Ludwig Enterprises) Business Description

Traded in Other Exchanges
N/A
Address
1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431
Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.